Pages that link to "Q40326219"
Jump to navigation
Jump to search
The following pages link to Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease (Q40326219):
Displaying 50 items.
- Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system (Q21090220) (← links)
- Astrocytes as a source for extracellular matrix molecules and cytokines (Q21129284) (← links)
- Oligonucleotide therapeutic approaches for Huntington disease (Q22306293) (← links)
- Calcitriol imparts neuroprotection in vitro to midbrain dopaminergic neurons by upregulating GDNF expression (Q24339450) (← links)
- Available and emerging treatments for Parkinson’s disease: a review (Q24633444) (← links)
- Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives (Q26747508) (← links)
- Miniaturized Technologies for Enhancement of Motor Plasticity (Q26752338) (← links)
- Chronic, intermittent convection-enhanced delivery devices (Q26776237) (← links)
- Neurotrophic Factors and Their Potential Applications in Tissue Regeneration. (Q26776474) (← links)
- GDNF-induced cerebellar toxicity: A brief review (Q26780274) (← links)
- Parkinson's disease gene therapy: success by design meets failure by efficacy (Q26851325) (← links)
- Adult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticity (Q26862840) (← links)
- Glial-derived neurotrophic factor gene transfer for Parkinson's disease: Anterograde distribution of AAV2 vectors in the primate brain (Q27002651) (← links)
- The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue? (Q27023715) (← links)
- Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? (Q27024152) (← links)
- Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease (Q27320553) (← links)
- Towards Clinical Application of Neurotrophic Factors to the Auditory Nerve; Assessment of Safety and Efficacy by a Systematic Review of Neurotrophic Treatments in Humans (Q28067169) (← links)
- GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease (Q28088320) (← links)
- Cell death in the nervous system (Q28269343) (← links)
- Neurotrophic factors as a therapeutic target for Parkinson's disease (Q28273071) (← links)
- TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial (Q28274460) (← links)
- Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial (Q28296434) (← links)
- Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation (Q28298280) (← links)
- Chemicals possessing a neurotrophin-like activity on dopaminergic neurons in primary culture (Q28475734) (← links)
- Rapid inverse planning for pressure-driven drug infusions in the brain (Q28486200) (← links)
- Clearance and toxicity of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHu GDNF) following acute convection-enhanced delivery into the striatum (Q28488443) (← links)
- Automated segmentation tool for brain infusions (Q28533650) (← links)
- Glial cell line-derived neurotrophic factor (GDNF) as a novel candidate gene of anxiety (Q28536350) (← links)
- Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease (Q28580559) (← links)
- A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys (Q28728201) (← links)
- Dopamine neuron stimulating actions of a GDNF propeptide (Q28748465) (← links)
- A synopsis on the role of tyrosine hydroxylase in Parkinson's disease (Q28830946) (← links)
- Parkinson's disease (Q29616302) (← links)
- Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound-mediated blood--brain barrier opening in vivo. (Q30387126) (← links)
- Protective effects of low-intensity pulsed ultrasound on aluminum-induced cerebral damage in Alzheimer's disease rat model (Q30413664) (← links)
- Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys (Q30581632) (← links)
- The role of biomarkers and imaging in Parkinson's disease. (Q31041660) (← links)
- Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. (Q31141544) (← links)
- Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons (Q33492743) (← links)
- Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease (Q33517934) (← links)
- Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects. (Q33600773) (← links)
- Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease (Q33636374) (← links)
- Nigral GFRα1 infusion in aged rats increases locomotor activity, nigral tyrosine hydroxylase, and dopamine content in synchronicity (Q33679788) (← links)
- Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications (Q33708288) (← links)
- Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain (Q33731226) (← links)
- Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse (Q33754804) (← links)
- Human/nonhuman primate AC-PC ratio--considerations for translational brain measurements (Q33780449) (← links)
- Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression (Q33807060) (← links)
- Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys (Q33819946) (← links)
- Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty (Q33851241) (← links)